Article Text

Download PDFPDF
Pancreatic cancer: an increasing global public health concern
  1. Citadel J Cabasag1,
  2. Jacques Ferlay1,
  3. Mathieu Laversanne1,
  4. Jerome Vignat1,
  5. Andras Weber1,2,
  6. Isabelle Soerjomataram1,
  7. Freddie Bray1
  1. 1 Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France
  2. 2 Hungarian National Cancer Registry, National Institute of Oncology, Budapest, Hungary
  1. Correspondence to Dr Citadel J Cabasag, Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France; cabasagc{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the commentary by Potjer highlighting the surveillance needs of individuals with a high risk of developing of pancreatic cancer (PC).1 The rationale in developing a comprehensive risk prediction model supporting earlier diagnosis is all the more valid given the poor prognosis and rising mortality of PC in many settings2 3 and the present gaps in our understanding of the underlying causes of the increase, as we highlight below.

In 2020, approximately 466 000 PC deaths were estimated worldwide with considerable variations in rates by country and region (figure 1).4 The disease can be considered a major public health concern globally given it ranks within the top 10 leading types of cancer death in over 130 countries. Further, PC mortality is …

View Full Text


  • Twitter @citadeljc

  • Contributors Study concept and design: FB. Data interpretation and drafting of manuscript: CJC and FB. Acquisition of data: JF, FB and IS. Statistical analysis: ML and JV. Critical revision for important intellectual content: all authors.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; internally peer reviewed.